SciNeuro

CompanyUnited States

SciNeuro develops one asset, in phase 2 (SNP318 in diabetic macular edema). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2
Raised
$53M
2
Trials
0
Signals

Pipeline

1
  • SNP318

    Phase 2, Small molecule, diabetic macular edema, DME

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials2
  • Funding rounds and grants1
  • Signals1
  • Similar companies6

Intelligence